In the field of tumor immunotherapy, novel tumor-targeting molecules such as single chain variable fragment (scFv) and nanobodies, or novel engineered protein modulators can be utilized to overcome tumor antigen escape and the harsh tumor microenvironment (TME). In a collaboration with TMU BIOMED Gloria, GenomeFrontier utilized our Protein/Target Hunter platform to successfully develop a number of therapeutic protein candidates that specifically target tumor antigens and/or modulating the TME. A brief schematic diagram of the Protein/Target Hunter plateforms is shown in Figure 1:
